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Background:  The  recombinant  yellow  fever-17D-dengue  virus,  live,  attenuated,  tetravalent  dengue vac-
cine (CYD-TDV)  has  undergone  extensive  clinical  trials.  Here  safety  and  consistency  of immunogenicity
of  phase  III manufacturing  lots  of CYD-TDV  were  evaluated  and  compared  with  a phase  II lot  and  placebo
in a  dengue-naïve  population.
Methods:  Healthy  18–60  year-olds  were  randomly  assigned  in a 3:3:3:3:1  ratio  to receive  three  sub-
cutaneous  doses  of either  CYD-TDV  from  any  one  of  three  phase  III lots  or  a phase  II lot,  or  placebo,
respectively  in  a 0, 6, 12  month  dosing  schedule.  Neutralising  antibody  geometric  mean  titres  (PRNT50
GMTs)  for  each  of  the  four dengue  serotypes  were  compared  in sera  collected  28 days  after  the third
vaccination—equivalence  among  lots  was  demonstrated  if the lower  and  upper  limits  of the  two-sided
95%  CIs  of the GMT  ratio  were  ≥0.5  and  ≤2.0,  respectively.
Results:  712  participants  received  vaccine  or placebo  and  614  (86%)  completed  the  study;  17  (2.4%)  par-
ticipants  withdrew  after  adverse  events.  Equivalence  of phase  III lots  was demonstrated  for  11 of  12
pairwise  comparisons.  One  of three  comparisons  for  serotype  2  was  not  statistically  equivalent.  GMTs
for  serotype  2  in  phase  III lots  were  close  to  each  other  (65.9,  44.1  and  58.1,  respectively).
Conclusions:  Phase  III lots  can  be produced  in  a  consistent  manner  with  predictable  immune  response
and  acceptable  safety  proﬁle  similar  to previously  characterised  phase  II lots.  The  phase  III lots  may
be  considered  as  not  clinically  different  as statistical  equivalence  was  shown  for serotypes  1, 3 and  4
across  the phase  III lots.  For serotype  2, although  equivalence  was  not  shown  between  two  lots,  the  GMTs
observed  in  the  phase  III lots  were  consistently  higher  than  those  for the  phase  II lot.  As  such,  in  our  view,
biological  equivalence  for all serotypes  was  demonstrated.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND∗ Corresponding author at: Department of Microbiology and Immunology, Uni-
ersity of Melbourne at The Peter Doherty Institute for Infection and Immunity, 792
lizabeth Street, Parkville, Melbourne 3000, VIC, Australia. Tel.: +61 3 90355570.
E-mail address: josepht@unimelb.edu.au (J. Torresi).
ttp://dx.doi.org/10.1016/j.vaccine.2015.08.008
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. IntroductionAlthough dengue is an endemic mosquito-borne viral disease in
tropical and sub-tropical regions of the world [1], current globalisa-
tion trends with increased intercontinental air travel and seaborne
trade have, in part, contributed to dengue becoming a major global
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ublic health threat in recent decades [2]. Globally, in 2010, there
ere an estimated 96 million apparent dengue infections and a
urther 294 million subclinical infections [3]. Current dengue con-
rol measures rely on targeting the mosquito vectors, but many
engue endemic countries do not have routine preventative vector
ontrol measures in place. These are usually implemented during
utbreaks (high transmission periods) and with methods of ques-
ionable effectiveness in reducing vector population density [4,5].
n addition, vector control measures, such as larval source reduc-
ion, are not sustainable indeﬁnitely with limited resources usually
eallocated to other competing needs once some sort of vector and
isease control has been achieved, allowing vector populations to
ebounded to levels sufﬁcient for epidemic transmission [6]. These
ailures have, in part, contributed to the increasing occurrence
f dengue epidemics and expansion of the geographical range of
ransmission. Although vaccination would likely represent an effec-
ive strategy for the management of dengue disease in endemic
egions, there is currently no licensed vaccine to prevent dengue
nfection and there is no speciﬁc antiviral treatment. In addition,
ravellers from non-endemic countries to endemic regions are at
igniﬁcant risk of dengue infection [7–9], and would also beneﬁt
rom an effective vaccine.
A recombinant yellow fever-17D–dengue virus, live, attenu-
ted, tetravalent dengue vaccine (CYD-TDV) is currently under
evelopment for the control of dengue disease. CYD-TDV has
ndergone extensive safety and immunogenicity assessment in
engue endemic and non-endemic populations [10–17]. To fulﬁl
he needs of phase III studies, the scale-up of CYD-TDV production
as been undertaken in parallel with its clinical development [18].
ifferences in the production of CYD-TDV lots used up to phase II
nd those used in phase III relate to the scale-up of the virus/cell
ulture. Other changes included the removal of human serum albu-
in  from the excipients and inclusion of a proprietary stabiliser in
he ﬁnished product [19].
This trial was conducted with the primary objective of testing
he safety and consistency of the immune responses elicited by
hree consecutive lots of vaccine from the scaled-up phase III pro-
uction process. Consistency studies are routinely undertaken for
ew biological products [20]. We  conducted this lot-to-lot consis-
ency study in people living in dengue-free areas of Australia in
rder to minimise the risk that natural infections would impact the
ssessment of the immune response following 3 doses of vaccine
r placebo, approximately 13 months after vaccination commenced
10,21–23].
. Methods
.1. Study design
This was a randomised, multi-centre, placebo-controlled,
bserver-blind, phase III study performed at eight centres
n Australia between 5 October 2010 and 12 June 2012
NCT01134263). The study was conducted in accordance with
he Declaration of Helsinki and the International Conference on
he Harmonization-Good Clinical Practice. The study protocol and
mendments were approved by the respective Institutional Review
oards or Independent Ethics Committees at each study site. Writ-
en informed consent was  obtained from all participants. The site
election criteria included locations outside of dengue endemic
egions..2. Participants
Healthy adults (aged 18 to 60 years) were eligible for inclu-
ion. Exclusion criteria included: pregnancy; breast feeding; history (2015) 5127–5134
of ﬂavivirus infection or vaccination; prolonged habitation in a
dengue endemic area (for more than 1 year); receipt of blood prod-
ucts within 3 months before enrolment, chronic illnesses including
alcohol and drug abuse that were at a stage that may  interfere with
trial conduct or completion; and congenital or acquired immuno-
deﬁciency or immunosuppressive conditions or treatments. Study
investigators were advised to avoid recruiting participants plan-
ning to travel to dengue endemic areas during the study period.
In the event that participants needed to travel to dengue endemic
areas during the trial, they were instructed on how to protect them-
selves against mosquito bites.
2.3. Random assignment and blinding
Participants were randomly assigned in permuted blocks of 13
(stratiﬁed by site) to one of ﬁve groups via an interactive voice
response system or interactive web  response system (IVRS/IWRS)
in a 3:3:3:3:1 ratio to receive either vaccine from any one of three
phase III lots, or a phase II lot, or placebo, respectively. At each site
a designated, unblinded vaccinator not involved in data collection
or safety assessments reconstituted and administered the assigned
vaccine or placebo.
2.4. Vaccines and placebo
Dengue vaccine was presented as a lyophilised powder and
saline solvent for reconstitution immediately before use in 0.5 mL
volumes containing 5 ± 1 log10 cell-culture infectious dose 50%
(CCID50) of each of the four live attenuated recombinant CYD vac-
cine virus serotypes. Solvent was  0.5 mL  NaCl 0.4% and human
serum albumin 2.5% for the phase II lots, and NaCl 0.4% without
human serum albumin for the phase III lots. The placebo was 0.5 mL
NaCl 0.9%. The study products were administered subcutaneously
in the deltoid region of the upper arm. Participants received a
3-dose series of injections scheduled at time-points 0, 6, and 12
months.
2.5. Immunogenicity assessments
Dengue neutralising antibody titres were determined on the
serum samples collected before the ﬁrst injection on Day 0 and
28 days (per-protocol range 28 to 32 days) after the third injec-
tion using a 50% plaque reduction neutralisation test (PRNT50) with
parental dengue virus strains of the four CYD-TDV constructs as
described previously (Sanoﬁ Pasteur GCI, Swiftwater, USA) [24,25].
The assay had a lower limit of quantiﬁcation titre of 10 (1/dilution):
titres below the lower limit of quantiﬁcation were assigned a value
of 5.
2.6. Reactogenicity and safety
All safety assessments were performed by staff blind to the
study product assigned to participants. Participants were moni-
tored for 30 min  after each injection for any immediate adverse
events/reactions. They were provided with digital thermometers,
ﬂexible rulers and diary cards and were instructed to record
solicited injection site reactions (pain, redness and swelling) for
7 days and systemic reactions (fever determined by axillary tem-
perature, headache, malaise, myalgia, asthenia) for 14 days, as well
as unsolicited adverse events for 28 days after each study injection.
All adverse events were graded on a three point scale as described
elsewhere [16]. Serious adverse events with onset at any time from
study enrolment to 6 months after the last injection were recorded.
Investigators assigned the causal relationship to study product for
each unsolicited adverse event and serious adverse event.
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Adverse events of special interest were hypersensitivity/allergic
eactions within 7 days of injection, viscerotropic disease or neu-
otropic disease within 30 days after each injection, and dengue
pisodes requiring hospitalization at any time during the study
26].
Women  who became pregnant during the study received no
urther study product and were followed for the duration of the
regnancy until outcome. A pregnancy was classed as “exposed” if
YD-TDV was administered within ≤30 days before the last men-
truation or thereafter.
.7. Deﬁnitions and statistical analyses
The primary objective was to demonstrate that three phase
II CYD-TDV lots induce equivalent immune responses in terms
f PRNT50 geometric mean titres (GMTs) against the four vaccine
arental strains 28 days after the third vaccination. Equivalence
mong the three phase III lots would be demonstrated if equiv-
lence was demonstrated for all serotypes. The GMTs for each
airwise lot-to-lot comparison were considered equivalent if the
ower and upper limits of the two-sided 95% conﬁdence intervals
CIs) of the GMT  ratio were ≥0.5 and ≤2.0, respectively [27,28]. The
5% CIs were calculated using the normal approximate method for
MTs. If equivalence of the three phase III lots was shown, a sec-
ndary objective was planned to test if the phase III vaccine (pooled
ata for all three lots) is equivalent to the phase II lot.
In order to have over 90% power to determine GMT  equivalence
etween the three phase III lots for all four serotypes and to provide
7.5% power for each serotype, assuming a 2-fold maximum accept-
ble difference between GMTs, an alpha level of 5% (two-sided
ypotheses), a standard deviation of 0.54 (log10 titres) for each
erotype, and that approximately 80% of participants would be
ncluded in the per-protocol analysis set, the sample size required
or each dengue vaccine group was set at 165. With a placebo con-
rol group of 55, the total sample size required was set at 715.
Statistical analyses were performed with SAS® software. PRNT50
itres and their 95% CIs were calculated for each of the four
erotypes assuming normal distribution of the log10 transformed
RNT50 titres.
The primary immunogenicity analyses were performed on the
er-protocol analysis set, and conﬁrmed on the full analysis set.
he per-protocol set included participants who met  all protocol-
peciﬁed inclusion criteria and did not meet any protocol-speciﬁed
xclusion criteria or deﬁnitive contraindications, received the cor-
ect doses of vaccine by the correct route and site of administration
ithin the speciﬁed times, provided a post-injection serum sample
ithin the speciﬁed time and were dengue seronegative at baseline
able 1
articipants’ baseline characteristics by randomly assigned groups (full analysis sets).
CYD-TDV 
Phase III lots 
Lot 1 (n = 163) Lot 2 (n = 162) 
Sex (n, %)
Male 60 (36.8) 75 (46.3) 
Age  (years, mean ± SD) 39.4 ± 13.3 39.4 ± 12.9 
Dengue status (n, %)‡
Seropositive 7 (4.3) 11 (6.8) 
Serotype 1 0 4 (2.5) 
Serotype 2 2 (1.2) 2 (1.2) 
Serotype 3 5 (3.1) 6 (3.7) 
Serotype 4 2 (1.2) 2 (1.2) 
‡ Dengue neutralising antibody titres were determined using a 50% plaque reduction ne
Sanoﬁ Pasteur GCI, Swiftwater, USA) [24,25]. Baseline dengue seropositivity was  deﬁne
1/dilution]) for at least one serotype. (2015) 5127–5134 5129
(PRNT50 titres below the lower limit of quantiﬁcation for each
serotype). The full analysis set consisted of all participants who
received at least one dose of CYD-TDV or placebo. The safety anal-
ysis set consisted of all vaccinated participants, analysed according
to the treatment received at the ﬁrst dose. The incidences of adverse
events were calculated along with the 95% CIs by allocated group.
Because this is the ﬁrst study involving adults aged older than
45 years, we undertook post-hoc exploratory comparisons of the
immunogenicity and safety data for adults aged 46 to 60 years to
that of younger adults aged 18 to 45 years.
3. Results
3.1. Study populations
Overall, 715 participants were enrolled and randomly assigned
to the study groups (Fig. 1). Of these, 712 received at least one study
injection, of whom 614 (86.2%) completed the study; 547 (76.8%)
were included in the per-protocol set. Withdrawals were evenly
distributed across study groups and were mainly voluntary (5.9%
of participants [42/712]). Six withdrawals occurred after serious
adverse events and 11 after other adverse events. The demographic
characteristics for enrolled participants are summarised in Table 1.
3.2. Antibody responses
The baseline seropositivity (PRNT50 titre ≥ 10) rates against each
of the dengue serotypes were broadly similar across the CYD-TDV
study groups (Table 1—FAS). Across the phase III lots, after comple-
tion of the third vaccination the seropositivity rates ranged from
59% to 71% for serotype 1, 78% to 86% for serotype 2, 91% to 95%
for serotype 3, and 91% to 92% for serotype 4. For the phase II lot,
post-vaccination seropositivity rates were 56%, 74%, 98% and 93%
for each serotype, respectively. There were no discernable increases
in seropositivity rates with placebo for serotypes 1 to 3, but a small
increase from 0% (95% CI: 0–6.3) to 14.6% (95% CI: 6.1–27.8) was
observed for serotype 4.
Compared to the baseline blood samples GMTs for the four
serotypes were greater across all CYD-TDV groups after the third
vaccination (Fig. 2—FAS). There was no discernable change to GMTs
with placebo compared to baseline: GMTs ranged 5.0 to 6.2 at base-
line and 5.6 to 6.6 after the third vaccination.
An exploratory analysis of the antibody response across all lots
in younger participants aged 18–45 years (n = 447) obtained the
following GMTs compared to older participants aged 46–60 years
(n = 265), respectively: 18.8 (16.4–21.7) vs. 17.7 (95% CI, 15.2–20.7)
for serotype 1; 47.2 (95% CI, 39.4–56.4) vs. 54.2 (95% CI 43.4–67.7)
Placebo (n = 57)
Phase II lot (n = 167)
Lot 3 (n = 163)
79 (48.5) 83 (49.7) 24 (42.1)
38.7 ± 14.1 38.4 ± 13.2 39.7 ± 13.5
8 (4.9) 17 (10.2) 5 (8.8)
2 (1.2) 6 (3.6) 4 (7.0)
1 (0.6) 4 (2.4) 3 (5.3)
3 (1.8) 10 (6.1) 4 (7.0)
6 (3.7) 6 (3.6) 0
utralisation test (PRNT50) with parental dengue virus strains of CYD-TDV constructs
d by dengue neutralisation antibodies above the lower limit of quantiﬁcation (10
5130 J. Torresi et al. / Vaccine 33 (2015) 5127–5134
Fig. 1. Flow of participants through the trial.
Fig. 2. Geometric mean titres (GMTs) and 95% CIs for each dengue serotype at baseline and 28 days following the third injection according to vaccine lot. Data shown for the
full  analysis set.
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Table  2
GMT  of antibodies against parental dengue virus serotypes among the CYD-TDV vaccine lots, placebo, and the phase III lot-to-lot comparisons 28 days after the third injection
(per-protocol set)† ,‡ .
Serotype 1 Serotype 2 Serotype 3 Serotype 4
GMT (95% CI)
Phase III
Lot 1 (n = 129) 20.6 (16.9; 25.1) 65.9 (50.6; 85.7) 74.2 (60.1; 91.7) 131.8 (101.4; 171.3)
Lot  2 (n = 123) 18.1 (14.8; 22.2) 44.1 (33.3; 58.3) 65.0 (53.2; 79.3) 94.6 (75.3; 118.7)
Lot  3 (n = 124) 17.1 (13.9; 21.2) 58.1 (43.2; 78.2) 71.6 (58.2; 88.2) 108.5 (84.2; 139.7)
Phase II
Lot (n = 128) 15.1 (12.4; 18.4) 25.7 (20.6; 32.0) 83.6 (71.1;98.4) 115.4 (92.8;143.5)a
Placebo (n = 43) 5 (NC) 5 (NC) 5 (NC) 6.09 (5.1; 7.4)
Lot–Lot comparisons GMT  ratio (95% CI)
Phase III
Lot 1/Lot 2 1.14 (0.86; 1.51) 1.49 (1.02; 2.19) 1.14 (0.86; 1.53) 1.39 (0.99; 1.97)
Lot  2/Lot 3 1.06 (0.79; 1.42) 0.76 (0.50; 1.14) 0.91 (0.68; 1.21) 0.87 (0.62; 1.22)
Lot  3/Lot 1 0.83 (0.63; 1.11) 0.88 (0.60; 1.31) 0.96 (0.72; 1.30) 0.82 (0.57; 1.18)
NC, not calculated. The lower limit of quantitation (LLOQ) of the assay was 10 (1/dil). For all calculations, any titre reported as <LLOQ was  converted to a value of 0.5 LLOQ.
a n = 127.
‡ Data are presented as GMT  (95% CIs) and GMT  ratios between paired lots (95% CIs). Lot-to-lot equivalence was demonstrated if the lower and upper limits of the two-sided
95%  CIs of the GMT  ratio were ≥0.5 and ≤2.0, respectively.
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n† The per-protocol set included participants who  met all protocol-speciﬁed inc
ontraindications, received the correct doses of vaccine within the speciﬁed times
RNT50 titres below the lower limit of quantiﬁcation for all 4 serotypes).
or serotype 2; 63.6 (95% CI, 55.1–73.5) vs. 83.3 (71.2–97.5) for
erotype 3; and 91.2 (95% CI, 75.2–111) vs. 144 (95% CI, 123–168)
or serotype 4.
.3. Equivalence analyses
Statistical equivalence of the GMTs for the 3 phase III lots was
emonstrated for 11 of 12 pairwise comparisons in the per-protocol
nalysis (Table 2). For one of three comparisons for serotype 2, the
MT  ratio between a pair of lots (lots 1 and 2) was 1.49 (95% CI:
.02; 2.19); i.e. the upper 95% CI exceeded the pre-set threshold of
.0. The same result was observed in the full analysis set (data not
hown).
Because the strict protocol-speciﬁed deﬁnition of phase III lot
quivalence had not been met, comparison of phase III lots (pooled
able 3
requency of solicited injection site and systemic reactions after any injection by group (
Symptom Severity CYD-TDV 
Phase III lots (n = 488) 
n/M % 95% CI 
Injection site reaction Any 231/481 48.0 43.5; 52.6 
Pain Any  220/481 45.7 41.2; 50.3 
Grade 3 3/481 0.6 0.1; 1.8 
Erythema Any  62/481 12.9 10.0; 16.2 
Grade 3 0/481 0 0; 0.8 
Swelling Any  14/481 2.9 1.6; 4.8 
Grade 3 0/481 0 0; 0.8 
Systemic reaction Any 366/481 76.1 72.0; 79.8 
Asthenia Any  157/481 32.6 28.5; 37.0 
Grade  3 23/581 4.8 3.1; 7.1 
Fevera Any 21/480 4.4 2.7; 6.6 
Grade 3 1/480 0.2 0; 1.2 
Headache Any  304/481 63.2 58.7; 67.5 
Grade  3 47/481 9.8 7.3; 12.8 
Malaise Any  244/481 50.7 46.2; 55.3 
Grade  3 46/481 9.6 7.1; 12.5 
Myalgia Any  210/481 43.7 39.2; 48.2 
Grade  3 25/481 5.2 3.4; 7.6 
, number of participants in speciﬁed category; M, number of participants available.
a Deﬁned by a temperature of ≥38.0 ◦C.
† The safety analysis set consisted of all vaccinated participants, analysed according to  criteria and did not meet any protocol-speciﬁed exclusion criteria or deﬁnitive
ded a post-injection serum sample and were dengue seronegative at baseline (i.e.
data) to the phase II lot could not proceed according to proto-
col. However, the pooled GMTs for the phase III vaccine lots for
serotypes 1, 3 and 4 after the third injection (18.6, 70.2 and 110.9,
respectively) were similar to those with the phase II lot (15.1, 83.6
and 115.4, respectively). For serotype 2, the GMTs were greater in
each individual phase III lot (65.9, 44.1 and 58.1) compared to the
phase II lot (25.7).
3.4. Reactogenicity and safety
The frequencies of adverse events following each of the three
injections are shown in Table 3 and Fig. 3. All the lots had a
similar reactogenicity and safety proﬁle. No deaths were reported.
Forty-four serious adverse events were reported by 34 participants;
5.0% [33/655] of CYD-TDV recipients and 1.8% [1/57] of placebo
safety analysis set)† .
Placebo (n = 57)
Phase II lot(n = 167)
n/M % 95% CI % 95% CI
84/164 51.2 43.3; 59.1 11/57 19.3 10.0; 31.9
78/164 47.6 39.7; 55.5 11/57 19.3 10.0; 31.9
0/164 0 0; 2.2 0/57 0 0.0; 6.3
24/164 14.6 9.6; 21.0 0/57 0 0.0; 6.3
0/164 0 0; 2.2 0/57 0 0.0; 6.3
5/164 3 1.0; 7.0 1/57 1.8 0.0; 9.4
0/164 0 0; 2.2 0/57 0 0.0; 6.3
125/164 76.2 69.0; 82.5 36/57 63.2 49.3; 75.6
69/164 42.1 34.4; 50.0 20/57 35.1 22.9; 48.9
9/164 5.5 2.5; 10.2 2/57 3.5 0.4; 12.1
5/164 3.0 1.0; 7.0 1/57 1.8 0.0; 9.4
0/164 0 0; 2.2 0/57 0 0.0; 6.3
104/164 63.4 55.5; 70.8 28/57 49.1 35.6; 62.7
14/164 8.5 4.7; 13.9 4/57 7.0 1.9; 17.0
90/164 54.9 46.9; 62.6 26/57 45.6 32.4; 59.3
13/164 7.9 4.3; 13.2 3/57 5.3 1.1; 14.6
84/164 51.2 43.3; 59.1 21/57 36.8 24.4; 50.7
13/164 7.9 4.3; 13.2 3/57 5.3 1.1; 14.6
the treatment received at the ﬁrst dose.
5132 J. Torresi et al. / Vaccine 33 (2015) 5127–5134
Fig. 3. Safety overview after the ﬁrst (a), second (b) and third (c) injections (safety analysis set). Data are shown with upper 95% conﬁdence limit.
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ecipients. Six participants (ﬁve CYD-TDV recipients and one
lacebo recipient) discontinued participation in the study follow-
ng serious adverse events, of which two were considered related to
YD-TDV vaccine: headache 10 days after the ﬁrst vaccination in a
9-year-old woman with hypertension, and polymyalgia rheumat-
ca in the month after the second vaccination in a 58-year-old man
ith underlying chronic osteoarthritis.
Eleven participants (all CYD-TDV recipients) had non-serious
dverse events leading to discontinuation—four of these (ery-
hematous rash, migraine, upper respiratory tract infection and
eriorbital infection) were assessed as related to the study product.
Immediate unsolicited adverse events occurred at a rate of 0.6%
4/655) after any injection with CYD-TDV. These events (facial ery-
hema, pruritus and dysgeusia, respectively, in three participants
ith the phase III vaccine, and dizziness in one participant with the
hase II vaccine) were of Grade 1 intensity and all resolved spon-
aneously within one day. There were no immediate unsolicited
dverse events in the placebo group.
Systemic and injection site unsolicited adverse events consid-
red vaccine-related were reported by 18% (90/488), 23% (39/167)
nd 18% (10/57) of participants in the pooled phase III, phase II, and
lacebo groups, respectively.
Older participants aged 46–60 years had a similar safety proﬁle
ompared with younger participants aged 18–45 years (data not
hown).
Among the adverse events of special interest sought, there
ere no cases of serious or severe allergic reactions, no serious
eurotropic or viscerotropic events, and no hospitalized dengue
isease reported. While allergic reactions within seven days after
tudy injection (1 pruritus, 7 rash, 1 facial swelling) were reported
y: 8/488 (2%) participants receiving any phase III vaccine and
/167 (1%) receiving the phase II vaccine, and none in the placebo
roup.
Four pregnancies were reported; all in CYD-TDV groups. One
regnancy was ‘exposed to vaccine’, i.e. the vaccine was adminis-
ered 18 days before the last menstrual period. The woman chose to
ave an elective abortion for unrelated personal reasons. The other
hree pregnancies were considered unexposed to the vaccine and
n each case a healthy infant was delivered at or near full-term.
. Discussion
This study was designed to establish the lot-to-lot consistency
f neutralising antibody responses produced by three phase III lots
f CYD-TDV. The secondary aims were: to demonstrate equivalence
f immune response of the phase III lots (pooled data) and a phase
I lot, and to describe the safety of CYD-TDV in an adult population
iving in dengue-free locations. As this is the largest CYD-TDV clin-
cal trial in adults to date, and the ﬁrst to use phase III vaccine lots
nd include adults older than 45 years, we could speciﬁcally assess
he immunogenicity and safety of CYD-TDV for the ﬁrst time in this
lder adult age group.
Equivalence between the phase III vaccine lots was statistically
emonstrated for 11 of the 12 comparisons, but not for the 12th
airwise comparison between lots 1 and 2 for serotype 2; thereby
ailing to satisfy the study’s strict per protocol equivalence deﬁ-
ition. However, equivalence between the phase III and II vaccine
ots was demonstrated for vaccine dengue serotypes 1, 3, and 4, but
ot for serotype 2. Two  factors that adversely affected the power of
he study may  account for this outcome. First, 76.8% of participants
ere eligible for inclusion in the per-protocol analysis while it had
een assumed that 80% would be included. In addition, at the plan-
ing stages of the study, the intrinsic variability of the neutralising
ntibody assay was assumed to be 2, but was later determined to
e 3 [25]. (2015) 5127–5134 5133
A post-hoc power analysis of the study observations revealed
that those two factors mentioned above reduced the power of the
study to determine equivalence to 62%. As lot-to-lot consistency
was not fully statistically demonstrated for all 12 comparisons, the
secondary objective of demonstrating equivalence between phase
III and phase II vaccine lots could not be formally undertaken as
described in the study protocol. Nevertheless, considering that only
one lot-to-lot comparison (Lot 1 versus Lot 2 for serotype 2) failed
the equivalence test by a narrow margin, we judge that biological
equivalence was  nonetheless established. The GMTs for serotype 2
were consistently higher in each individual phase III lot compared
to the phase II lot. Therefore, although consistency for serotype 2
was narrowly missed between two  phase III lots, the phase III lots
may  be considered as not clinically different.
There were no safety concerns with CYD-TDV in this study.
The safety and reactogenicity proﬁle of the vaccine lots was
acceptable and consistent with previous CYD-TDV clinical trials
[10,11,13,14,19]. Both the phase III and phase II vaccines in this
study were equally well tolerated, with reporting patterns for
the different categories of adverse events and reactions similar
between groups. There was a trend of reduced reactogenicity with
second and third dose of CYD-TV compared to the ﬁrst dose (Fig. 2).
Most of the local and systemic reactions were of mild intensity, and
of short duration. CYD-TDV had a similar safety and tolerability
proﬁle in participants older than 45 years compared with younger
participants (see Supplementary Fig. S1).
The immunogenicity proﬁles of the phase III and phase II vaccine
lots tested in this study were consistent with those observed in two
phase II studies in non-endemic areas, one conducted in healthy
adults in the USA [13] using the same study product and vaccina-
tion schedule as the current study, and the other in dengue-naïve
children, adolescents, and adults in Mexico City using a slightly
different vaccination schedule [12].
There is no recognised PRNT50 seroprotection threshold for any
dengue serotype yet. Two of the three phase III vaccines lots in our
study were also used in two  phase III studies conducted in South
East Asia (10,275 children aged 2 to 14 years) [29] and Latin America
(20,869 children aged 9 to 16 years) [30]. One year of follow-up,
beginning 28 days after the third dose of vaccine, showed that CYD-
TDV had 56.5% and 60.8% efﬁcacy (with narrow 95% conﬁdence
intervals) against virologically-conﬁrmed dengue in the two phase
III studies, respectively. Additional analyses of the phase III efﬁcacy
trials may  provide information on potential PRNT50 seroprotection
threshold values.
In summary, these results support the change in manufactur-
ing process required for the scaled up production of the CYD-TDV.
There were no safety concerns observed in this study with the
CYD-TDV, and the vaccination schedule was well tolerated.
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